2010-11-24
Optimizing Treatment Strategies Using Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B
Publication
Publication
Antivirale behandeling van chronische hepatitis B: het optimaliseren van behandelstrategieën met nucleos(t)ideanalogen
Hepatitis B infection has a complex natural history and causes a wide spectrum of disease. Although effective vaccines are available, universal vaccination has yet not been reached. Currently, an estimated 350 million people are chronically infected, and 0.5-1.2 million subjects die every year due to long-term sequalae of hepatitis B related chronic liver disease, such as liver cirrhosis and hepatocellular carcinoma Despite evidence-based treatment guidelines areas of disagreement on the management of chronic hepatitis B virus (HBV) infection still exist. With the currently approved treatment options the ultimate goal is to prevent the development of long-term sequelae of chronic liver disease. Current treatment strategies consist of either therapies with fi nite duration that aims to achieve sustained off-treatment remission (interferon-based therapy), or long-term therapy that aims to maintain on-treatment response (nucleos(t)ide analogues).
| Additional Metadata | |
|---|---|
| , , , , | |
| Erasmus MC Rotterdam, Nederlandse Vereniging voor Gastroenterologie, Novartis, Gilead Sciences, Bristol-Myers Squibb, J.E. Jurriaanse Stichting | |
| H.L.A. Janssen (Harry) | |
| Erasmus University Rotterdam | |
| hdl.handle.net/1765/21420 | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Reijnders, J. (2010, November 24). Optimizing Treatment Strategies Using Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B. Retrieved from http://hdl.handle.net/1765/21420 |
|
| Additional Files | |
|---|---|
| Jurrien stellingen.pdf , 21kb | |
| 3204_Reijnders, Jurrien Gerben Peter.jpg Cover Image , 19kb | |
